Brivanib Drug

See: Fibroblast Growth Factor, Bristol-Myers Squibb, Hepatocellular Carcinoma, Liver Cancer, Tyrosine Kinase Inhibitor, NCT00437424 Clinical Trial.

References

FDA. (2017). “22 Case Studies Where Phase 2 and Phase 3 Trials Had Divergent Results."
- QUOTE: ... To treat those patients who do not respond to sorafenib or who have severe side effects related to the drug, brivanib was developed. Brivanib inhibits a novel growth factor, in addition to those growth factors targeted by sorafenib. ...
  ... Several phase 3 RCTs designed to isolate the effects of brivanib, confirmed statistically significant antitumor activity, but found no evidence that treatment with brivanib improves the overall survival of patients with HCC. ...

(Wikipedia, 2022) ⇒ https://en.wikipedia.org/wiki/Brivanib_alaninate Retrieved:2022-11-11.
- Brivanib alaninate (INN/USAN) also known as BMS-582664 is an investigational, anti-tumorigenic drug for oral administration. The drug is being developed by Bristol-Myers Squibb for the treatment of hepatocellular carcinoma or HCC (also called malignant hepatoma), the most common type of liver cancer. Brivanib is no longer in active development.
  Brivanib alaninate is a multitargeted tyrosine kinase inhibitor (as is sorafenib).
  Brivanib alaninate also inhibits VEGFR and fibroblast growth factor receptors (FGFR), which is known to play a major role in the etiopathogenesis of HCC. To date, brivanib alaninate has been investigated in 29 studies, including more than 4,000 patients around the world.